Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas.
Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas.
复制标题
盐酸氮芥和环磷酰胺治疗霍奇金病和淋巴瘤。
DOI：
--
复制
发表时间：
1968
期刊：
影响因子：
--
通讯作者：
D. Wood
中科院分区：
文献类型：
--
作者：
E. Jacobs;F. C. Peters;J. Luce;C. Zippin;D. Wood
86名患者（37名患有霍奇金病，37名患有淋巴肉瘤，12名患有网状细胞肉瘤）被随机分组，分别接受单剂量盐酸甲氯他明（0.4 mg/kg体重，静脉注射），然后每天使用氯苯bucil（口服）维持治疗，或使用环磷酰胺（40 mg/kg体重，静脉注射），然后每天使用环磷酰胺（口服）维持治疗。两种方案在客观肿瘤反应的频率上没有显著差异：45%的接受氯胺酮治疗的患者和57%接受环磷酰胺治疗的患者有客观反应。明显的脱发是毒性作用的唯一显著差异，在接受环磷酰胺治疗的患者中有36%出现脱发，而接受氯胺治疗的患者中有1例出现脱发。环磷酰胺相对于氯胺酮和氯霉素有轻微的血小板保护作用，但没有临床意义。
Eighty-six patients (37 with Hodgkin's disease, 37 with lymphosarcoma, and 12 with reticulum cell sarcoma) were randomized and treated with either a single dose of mechlorethamine hydrochloride (0.4 mg/kg of body weight, given intravenously) followed by daily maintenance with chlorambucil (given orally), or a loading dose of cyclophosphamide (40 mg/kg of body weight, given intravenously) followed by daily maintenance with cyclophosphamide (given orally). No significant difference was observed between these two regimens in frequency of objective tumor response: 45% of patients who received mechlorethamine and 57% who received cyclophosphamide had an objective response. Marked alopecia was the only significant difference in toxic effects, occurring in 36% of the patients receiving cyclophosphamide and in one patient receiving mechlorethamine. A slight plateletsparing effect of cyclophosphamide over mechlorethamine and chlorambucil was not considered clinically significant.